Company: TVRD
Filing Date: 2025-02-14
Form Type: S-4/A
Source: 0001104659-25-013053
Chunk: 762

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-02-14
Form: S-4/A
Chunk 762
---
|
| Raw materials                           | ​ | ​ | ​                 | $ |  2,124 | ​ | ​ | ​ | ​                | $ | 2,639 | ​ | ​ |
| Work-in-process                         | ​ | ​ | ​                 | ​ |     16 | ​ | ​ | ​ | ​                | ​ |   708 | ​ | ​ |
| ​                                       | ​ | ​ | ​                 | ​ |  2,140 | ​ | ​ | ​ | ​                | ​ | 3,347 | ​ | ​ |
| Less Inventory Reserve for Obsolescence | ​ | ​ | ​                 | ​ | -1,515 | ​ | ​ | ​ | ​                | ​ |  -526 | ​ | ​ |
| Total                                   | ​ | ​ | ​                 | $ |    625 | ​ | ​ | ​ | ​                | $ | 2,821 | ​ | ​ |

As of September 30, 2024 and December 31, 2023, inventory balances include inventory costs subsequent to regulatory approval of KORSUVA injection on August 23, 2021. During the three and nine months ended September 30, 2024, the Company wrote down $1,020 and $2,509, respectively, of commercial supply inventory due to obsolescence. 8. Prepaid expenses As of September 30, 2024, prepaid expenses were $2,382, consisting of $1,650 of prepaid R&D clinical costs, $561 of prepaid insurance and $171 of other prepaid costs. As of December 31, 2023, prepaid expenses were $8,154, consisting of $7,245 of prepaid R&D clinical costs, $492 of prepaid insurance, and $417 of other prepaid costs.

F-16

TABLE OF CONTENTS

CARA THERAPEUTICS, INC. NOTES TO CONDENSED FINANCIAL STATEMENTS
(amounts in thousands, except share and per share data)
(unaudited) 9. Accounts Payable and Accrued Expenses Accounts payable and accrued expenses consist of the following:

| ​                                   | ​ | ​ | September 30,2024 |   |       |   | ​ | ​ | December 31,2023 |   |        |   | ​ |
|:------------------------------------|:--|:--|:------------------|:--|------:|:--|:--|:--